Content
Frontiers of Medicine >> 2021, Volume 15, Issue 2 doi: 10.1007/s11684-020-0812-7
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA 30322, USA
Abstract
Keywords
mTOR ; cancer therapy ; resistance ; GSK3 ; protein degradation ; E3 ubiquitin ligase ; PD-L1
Content